Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. The compound carries the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and has been widely studied in preclinical and early clinical research for its potential anxiolytic and nootropic properties. Unlike many compounds investigated in the neuroscience space, Selank research suggests a unique dual profile — scientists have examined both its calming effects and its apparent capacity to support cognitive function simultaneously, a combination that has drawn significant attention in peptide research circles.
Over the past several decades, Selank research has expanded considerably beyond its original immunological context. Investigations into its interaction with GABAergic systems, BDNF expression, and enkephalin metabolism have made it a compelling subject for laboratories studying stress, anxiety modeling, and learning paradigms. This guide provides a structured overview of what the science currently reveals about Selank’s mechanisms, how it compares to related peptides in research settings, and what questions remain open for further study.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. Selank and all peptides referenced in this article are intended strictly for in vitro and preclinical laboratory research use.
Selank - 5MG — Research-Grade Reference Material Selank - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
PT-141 - 10MG
$50.00$37.50 with 1st order
Ara-290 10MG
$45.00$33.75 with 1st order
MOTS-C - 10MG
$45.00$33.75 with 1st order
Frequently Asked Questions
What is Selank peptide?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory peptide tuftsin. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and has been studied preclinically for potential anxiolytic and cognitive-enhancing properties.
How does Selank work in research models?
Research suggests Selank may interact with GABAergic signaling pathways, influence BDNF (brain-derived neurotrophic factor) expression, and modulate enkephalin metabolism. These mechanisms are studied in preclinical animal models and do not constitute verified therapeutic actions in humans.
What is Selank studied for in laboratory settings?
Preclinical studies have investigated Selank in the context of anxiety modeling, stress response, memory and learning paradigms, immune modulation, and neuroprotection. Researchers also study its effects on cytokine expression and serotonin metabolism.
How does Selank compare to Semax in research?
Both Selank and Semax are synthetic neuropeptides studied for cognitive and neurological effects. Research suggests Selank leans more toward anxiolytic properties and stress modulation, while Semax research has focused more heavily on neuroprotection, BDNF upregulation, and cognitive enhancement under stress conditions. They are often studied in complementary paradigms.
Is Selank the same as tuftsin?
Selank is derived from tuftsin but is not identical to it. Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg), while Selank is an analog with an additional Pro-Gly-Pro sequence appended to enhance metabolic stability and extend biological activity in research models.
What does BDNF have to do with Selank research?
Several studies have investigated Selank’s influence on BDNF (brain-derived neurotrophic factor) expression. BDNF plays a key role in neuroplasticity, synaptic maintenance, and learning. Researchers have explored whether Selank-induced changes in BDNF levels may correlate with observed improvements in memory tasks and anxiety-related behaviors in animal models.
What is the research status of Selank?
Selank has been investigated in both preclinical (animal) and some limited clinical research, primarily in Russia where it has been studied as an anxiolytic compound. In most Western research contexts, it is studied as a research peptide in preclinical models only. It is not approved as a therapeutic agent in most jurisdictions.
Can Selank be stacked with other peptides in research?
In research settings, Selank has been studied alongside compounds like Semax, particularly in models examining cognitive and mood-related endpoints. Researchers sometimes design experiments comparing or combining neuropeptides to evaluate synergistic or complementary signaling profiles in preclinical paradigms.
The Origins of Selank: From Tuftsin to a Stabilized Research Analog
To understand Selank’s research significance, it helps to examine where it came from. Tuftsin is an endogenous tetrapeptide produced through enzymatic cleavage of the Fc region of immunoglobulin G. It is naturally involved in immune activation — particularly in stimulating phagocytosis and modulating macrophage activity. Scientists at the Institute of Molecular Genetics of the Russian Academy of Sciences recognized that tuftsin possessed interesting biological activity but suffered from extremely rapid enzymatic degradation, limiting its utility in research models.
Selank - 5MG — Research-Grade Reference Material Selank - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
PT-141 - 10MG
$50.00$37.50 with 1st order
Ara-290 10MG
$45.00$33.75 with 1st order
MOTS-C - 10MG
$45.00$33.75 with 1st order
To address this, researchers appended the sequence Pro-Gly-Pro to the C-terminus of tuftsin’s Thr-Lys-Pro-Arg sequence, creating the stabilized heptapeptide now known as Selank. This structural modification was found in early studies to significantly extend the compound’s half-life in biological environments, making it far more tractable as a research tool. The resulting molecule retained the parent peptide’s immunomodulatory profile while also exhibiting a broader range of neurobiological activity — a finding that redirected much of the subsequent Selank research toward the central nervous system.
Selank’s Proposed Mechanisms in Preclinical Research
GABAergic Signaling Modulation
One of the most frequently cited mechanisms in Selank research involves the GABAergic system. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the mammalian central nervous system, and its dysregulation is centrally implicated in anxiety and stress disorders as studied in animal models. Research has investigated whether Selank modulates GABA-A receptor function in ways that parallel, but may differ mechanistically from, classical benzodiazepine activity. Importantly, studies have examined whether Selank produces comparable anxiolytic effects without the sedative, amnestic, or dependence-related profiles observed with direct GABAergic agonists — a key area of interest for researchers studying anxiolytic mechanisms.
BDNF Expression and Neuroplasticity Research
Brain-derived neurotrophic factor (BDNF) is a critical regulator of neuroplasticity, synaptic strength, and long-term potentiation. Studies have explored Selank’s capacity to upregulate BDNF expression in hippocampal and cortical tissue in rodent models. This line of research is particularly relevant to investigators studying memory consolidation and learning, as BDNF plays a well-established role in both processes. Elevated BDNF has been correlated in Selank-treated animal cohorts with improved performance on maze-based learning tasks, though the precise molecular cascade linking Selank binding to BDNF transcription remains an active area of inquiry.
Enkephalin Metabolism and Endogenous Opioid Systems
Selank has been investigated for its potential to inhibit enkephalin-degrading enzymes, thereby extending the activity of endogenous opioid peptides. Enkephalins are involved in pain modulation, emotional regulation, and stress response. Research suggests that Selank may act as a competitive inhibitor of enkephalinase enzymes, resulting in higher synaptic concentrations of endogenous enkephalins. This mechanism is distinct from exogenous opioid receptor agonism and has been explored as a potentially cleaner pathway for modulating stress-related neurotransmission in preclinical paradigms.
Serotonin and Dopamine Pathway Research
Several studies have examined Selank’s effects on monoamine neurotransmitter systems, particularly serotonin and dopamine. Research in rodent models has reported altered expression of genes encoding serotonin metabolism enzymes following Selank administration. The compound has been studied in relation to the serotonergic system’s role in anxiety-related behaviors, while its potential dopaminergic activity has been investigated in the context of reward, motivation, and cognitive drive in preclinical models.
Selank in Anxiety and Stress Research Models
The most extensively published area of Selank investigation involves anxiety and stress paradigms. Animal models commonly used in this research include the elevated plus maze, the open-field test, and the forced swim test — all standard assays for evaluating anxiolytic and antidepressant-like compound profiles. Research has consistently reported that Selank-treated rodents show behaviors consistent with reduced anxiety, including increased time in open maze arms and decreased freezing behavior under threat exposure, compared to control cohorts.
A particularly notable line of inquiry has examined whether Selank’s anxiolytic profile in these models is accompanied by cognitive impairment — a common limitation of classical anxiolytics such as benzodiazepines. Multiple preclinical studies have suggested that Selank does not replicate the memory deficits or motor coordination impairment seen with benzodiazepine comparators in rodent models, a finding that has made it a subject of considerable interest for researchers seeking cleaner tools for anxiety pathway investigation.
Selank in Cognitive and Nootropic Research
Beyond its anxiolytic research profile, Selank has been studied extensively in cognitive paradigms. Investigations have explored its effects on spatial learning, working memory, and attention in rodent models. The compound’s dual profile — appearing to reduce anxiety-related interference while simultaneously supporting BDNF-mediated plasticity pathways — makes it an interesting tool for researchers studying the intersection of stress, emotion, and cognitive performance.
Studies using radial arm maze and Morris water maze protocols have reported improved performance metrics in Selank-treated cohorts, with researchers hypothesizing that both the reduction of anxiolytic interference and the direct neurotrophin effects may contribute to observed outcomes. This cognitive research dimension places Selank in a similar space to Semax, though the two peptides appear to exert their effects through partially distinct molecular pathways.
For researchers interested in comparing nootropic peptide profiles, Semax offers a closely related but mechanistically distinct research compound for cross-compound study designs.
Immunomodulatory Research: Selank’s Origins Revisited
Given Selank’s derivation from the immune-active peptide tuftsin, researchers have also investigated its immunomodulatory properties. Studies have examined Selank’s effects on cytokine expression profiles, particularly in models of immune activation and neuroinflammation. Research has reported that Selank may modulate the balance between pro-inflammatory and anti-inflammatory cytokines, including interleukin-6 (IL-6) and interferon-gamma, in preclinical settings.
This immune-brain axis research is particularly relevant in the context of growing scientific interest in neuroinflammation as a substrate for mood and cognitive disorders. Researchers studying the relationship between systemic inflammation and CNS function have investigated Selank as a potential tool for modulating this interface in animal models, though this work remains at an early, exploratory stage.
Selank vs. Semax: A Researcher’s Comparison
Selank and Semax are frequently studied in parallel given their shared origins in Russian peptide pharmacology and their overlapping yet distinct research profiles. The following table summarizes the key differences as understood from the current preclinical literature.
| Feature | Selank | Semax |
|---|---|---|
| Peptide origin | Tuftsin analog (heptapeptide) | ACTH(4-7) analog (heptapeptide) |
| Primary research focus | Anxiolytic, stress modulation | Neuroprotection, cognitive enhancement |
| BDNF modulation | Investigated — upregulation reported | Extensively studied — robust upregulation |
| GABAergic involvement | Strongly implicated in research | Less directly studied |
| Enkephalin pathway | Studied as potential enkephalinase inhibitor | Not a primary research focus |
| Cognitive research | Memory and learning models studied | Extensively studied under stress/ischemia models |
| Immunomodulation | Strong tuftsin-derived profile | Limited immunological data |
| Research profile summary | Anxiolytic + mild nootropic | Nootropic + neuroprotective |
Choose Selank if…
- Your research focus involves GABAergic anxiety modeling
- You are studying enkephalin metabolism or endogenous opioid systems
- Your protocols include immune-CNS axis investigations
- You are comparing anxiolytic profiles without sedative confounders
Choose Semax if…
- Your research centers on BDNF-driven neuroplasticity or neuroprotection
- Your models involve ischemic or oxidative stress conditions
- You are focused primarily on cognitive performance under neurological challenge
- Your protocol requires a more robustly characterized nootropic comparator
Research Considerations and Open Questions
While the preclinical literature on Selank is relatively well-developed compared to many research peptides, several important questions remain open. The precise receptor binding profile of Selank has not been fully characterized — researchers have proposed GABA-A modulation and enkephalinase inhibition as key mechanisms, but a comprehensive receptor binding map has yet to be published. Additionally, the dose-response relationship in different model systems shows variability across studies, underscoring the need for careful protocol standardization in any research design involving Selank.
Researchers should also note that the majority of Selank studies have been conducted in Russian academic and clinical settings, which may introduce considerations around methodological variability and reproducibility in Western laboratory contexts. Independent replication of key findings — particularly around the BDNF upregulation and GABAergic modulation profiles — represents an important frontier for the field.
Where These Fit in Your Research Library
Selank occupies a distinctive niche in the peptide research landscape — positioned at the intersection of anxiety biology, cognitive neuroscience, and immunomodulation. For laboratories building out a neuropeptide research library, it pairs naturally with Semax for comparative CNS studies, and may also complement investigations involving BDNF-targeting or neuroinflammation compounds.
Explore the full catalog for additional neuropeptide and cognitive research compounds: SourcePeptides Research Catalog →
Final Takeaway
Selank is a well-characterized synthetic heptapeptide with a multi-faceted preclinical research profile spanning anxiolytic activity, cognitive modulation, BDNF expression, enkephalin metabolism, and immunomodulation. Its derivation from tuftsin gives it a unique immunological heritage, while its apparent capacity to reduce anxiety-related behaviors in animal models without the cognitive side-effect profile of classical anxiolytics has made it a particularly interesting research tool for CNS-focused investigators. Studies have investigated its interaction with GABAergic systems, serotonin and dopamine pathways, and neurotrophic factor expression — collectively painting a picture of a peptide with broad but targeted neurobiological activity. For researchers designing protocols around stress, anxiety, neuroplasticity, or immune-CNS interface questions, Selank represents a compelling and scientifically grounded addition to the research toolkit.
Sources & Further Reading
- Semenova TP et al. — “Selank: effects on learning and memory in rats” — Eksperimental’naia i Klinicheskaia Farmakologiia (2001)
- Uchakina ON et al. — “Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders” — Zhurnal Nevrologii i Psikhiatrii (2008)
- Zozulya AA et al. — “The characterization of Selank as a potential anxiolytic compound” — Neurochemical Journal (2014)
- PubMed Search — Selank BDNF Research Studies
- PubMed Search — Tuftsin Neuropeptide Analog Research
